New diabetes drug tested in everyday clinics

NCT ID NCT07433192

Recruiting now Disease control Sponsor: Servier Russia Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is observing 300 adults with type 2 diabetes who are already taking luseogliflozin as part of their routine care. Researchers will track changes in blood sugar levels, body weight, and side effects over time. The goal is to see how well the drug works in real-world settings, outside of strict research conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: luseogliflozin (a diabetes drug that helps lower blood sugar by making the kidneys remove more sugar in urine)
What this could lead to: If successful, this study could confirm that luseogliflozin works well and is safe for managing type 2 diabetes in everyday medical practice.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It is also early-stage and only includes patients already taking the drug, which may limit conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

GBUZ hospital
RECRUITING

Anapa, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.